Finch Therapeutics Reclaims Full Control of Fin-524 and Fin-525: Promising Microbiome Products for IBD Development
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Micro… SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH) Finch Therapeutics, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, has announced that it…